Navigation Links
AMT Announces Presentations During the 11th Annual Meeting of the ASGT

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a series of presentations during the 11th Annual Meeting of the American Society of Gene Therapy in Boston, including a presentation on the pivotal clinical trial with its lead product AMT-011 on May 29.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... DunAn ... (USHX) product, launches today on the Android smartphone platform. Southern Case Arts, producers ... remote control and monitoring capability for the first time to the market at ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... culture, and assessment of organotypic 3D cell culture models, has launched a ... screening in their patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines ...
(Date:10/13/2015)... October 13, 2015 " Microbiology Culture ... 2015 - 2023 " , the global microbiology ... anticipated to reach US$7.59 bn by 2023, expanding at a CAGR ... --> " Microbiology Culture Market - Global Industry Analysis, ... , the global microbiology culture market was valued at ...
(Date:10/13/2015)... 13, 2015      Q BioMed ... has entered into a strategic relationship with Wombat Capital, ... Paris, France based strategic and ... --> This collaborative arrangement gives Q BioMed and ... team as well as long established pharmaceutical industry relationships. ...
Breaking Biology Technology:
(Date:10/2/2015)... , Oct. 02 2015 ... the "Enforcing the Law Using Biometrics" ... ) has announced the addition of the ... their offering. --> Research and Markets ... the "Enforcing the Law Using Biometrics" ...
(Date:9/30/2015)... BEACH GARDENS, Fla. , Sept. 30, 2015 /PRNewswire/ ... earlier this month issued another key ruling in favor ... (ITC,s) determination that Korean fingerprint scanner company Suprema and ... Tariff Act of 1930, a trade provision that declares ... with import trade, by infringing two of Crossmatch,s patents, ...
(Date:9/29/2015)... 29, 2015  iDAvatars is excited to be named one ... to market. The official announcement was recently made at an ... in San Francisco , where iDAvatars presented ... IBM Watson. "It is both an honor and ... to bring to market the cognitive power of IBM Watson ...
Breaking Biology News(10 mins):